menu
    • menu
    [{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Financing","leadProduct":"Lutetium-177-edotreotide","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Blue Owl Capital","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Blue Owl Capital"}]

    Find Clinical Drug Pipeline Developments & Deals for Lutetium-177-edotreotide

    Menu

    Lutetium-177-edotreotide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Isotope Technologies Munich

                            Germany arrow
                            DIA 2025
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177-edotreotide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Blue Owl Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds

                            Details : The financing aims to advance the clinical development of ITM-11 (177Lu-Edotreotide), which is being evaluated for the Gastroenteropancreatic Neuroendocrine Tumors.

                            Product Name : ITM-11

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : Lutetium-177-edotreotide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Blue Owl Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth